AIM: To evaluate the outcomes among elderly (≥70 years) and younger patients (<70 years) with liver-dominant metastatic colorectal cancer (mCRC) who received radioembolization (RE) as salvage therapy. METHODS: A retrospective review of 107 consecutive patients with unresectable mCRC treated with RE after failing first- and second-line chemotherapy. RESULTS: From 2002 to 2012, 44 elderly and 63 younger (<70 years) patients received RE. Patients had similar previous extensive chemotherapy and liver-directed interventions. Using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria, either a stable or a partial radiographical response was seen in 65.8% of the younger compared with 76.5% of the elderly patients. RE was equally well tolerated in both groups and common procedure-related adverse events were predominantly grade 1-2 and of short duration. No significant difference was found with regard to overall median survival between younger [8.4 months; 95% confidence interval (CI) = 6.2-10.6] or elderly patients (8.2 months; 95% CI = 5.9-10.5, P = 0.667). The presence of extrahepatic disease at the time of RE was associated with a significantly worse median survival in both groups. CONCLUSION: Radioembolization appears to be as well tolerated and effective for the elderly as it is for younger patients with mCRC. Age alone should not be a discriminating factor for the use of radioembolization in the management of mCRC patients.
AIM: To evaluate the outcomes among elderly (≥70 years) and younger patients (<70 years) with liver-dominant metastatic colorectal cancer (mCRC) who received radioembolization (RE) as salvage therapy. METHODS: A retrospective review of 107 consecutive patients with unresectable mCRC treated with RE after failing first- and second-line chemotherapy. RESULTS: From 2002 to 2012, 44 elderly and 63 younger (<70 years) patients received RE. Patients had similar previous extensive chemotherapy and liver-directed interventions. Using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria, either a stable or a partial radiographical response was seen in 65.8% of the younger compared with 76.5% of the elderly patients. RE was equally well tolerated in both groups and common procedure-related adverse events were predominantly grade 1-2 and of short duration. No significant difference was found with regard to overall median survival between younger [8.4 months; 95% confidence interval (CI) = 6.2-10.6] or elderly patients (8.2 months; 95% CI = 5.9-10.5, P = 0.667). The presence of extrahepatic disease at the time of RE was associated with a significantly worse median survival in both groups. CONCLUSION: Radioembolization appears to be as well tolerated and effective for the elderly as it is for younger patients with mCRC. Age alone should not be a discriminating factor for the use of radioembolization in the management of mCRC patients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Alain Hendlisz; Marc Van den Eynde; Marc Peeters; Geert Maleux; Bieke Lambert; Jaarke Vannoote; Katrien De Keukeleire; Chris Verslype; Luc Defreyne; Eric Van Cutsem; Philippe Delatte; Thierry Delaunoit; Nicola Personeni; Marianne Paesmans; Jean-Luc Van Laethem; Patrick Flamen Journal: J Clin Oncol Date: 2010-06-21 Impact factor: 44.544
Authors: M Egenvall; K Schubert Samuelsson; I Klarin; J Lökk; A Sjövall; A Martling; U Gunnarsson Journal: Colorectal Dis Date: 2014-06 Impact factor: 3.788
Authors: James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: Gary W Nace; Jennifer L Steel; Nikhil Amesur; Albert Zajko; Bryon E Nastasi; Judith Joyce; Michael Sheetz; T Clark Gamblin Journal: Int J Surg Oncol Date: 2011-03-20
Authors: Ieva Kurilova; Regina G H Beets-Tan; Jessica Flynn; Mithat Gönen; Gary Ulaner; Elena N Petre; F Edward Boas; Etay Ziv; Hooman Yarmohammadi; Elisabeth G Klompenhouwer; Andrea Cercek; Nancy A Kemeny; Constantinos T Sofocleous Journal: Clin Colorectal Cancer Date: 2018-09-13 Impact factor: 4.481
Authors: Thomas Walter; Neil S Hawkins; Richard F Pollock; Fabien Colaone; Suki Shergill; Paul J Ross Journal: J Cancer Res Clin Oncol Date: 2020-07-27 Impact factor: 4.553
Authors: Nyan Y Khin; Madhawa De Silva; Stephen Clarke; Nick Pavlakis; Chris M Rogan; Kevin Ho-Shon; Rodney J Lane Journal: Ann Surg Oncol Date: 2022-02-11 Impact factor: 4.339